On May 24-25, 2018, a scientific and practical conference “Topical Issues of Upper Limb Surgery, Arthroscopy and Sports Trauma” was held in Lviv for traumatologists and orthopedic surgeons. The organizers of the conference were the All-Ukrainian NGO “Ukrainian Association of Sports Traumatology”, the All-Ukrainian NGO “Ukrainian Association of Sports Traumatology, Knee Surgery and Arthroscopy”, and the All-Ukrainian NGO “Ukrainian Association of Hand Surgery”. The conference was attended by leading domestic specialists and scientists from the USA, France, Germany, Austria, Italy, Poland, China, Russia.
The program of the conference dealt with the matters of injuries and upper arm diseases, surgery of elbow joint, hand, wrist, arthroscopic interventions on the upper limb, regenerative medicine in orthopedics and traumatology, the matters of diagnostics and treatment of complications of sports injuries, etc.
During the conference the Pharmaceutical Firm “Darnitsa” presented the stand, which showed medicinal products of its own production. The product portfolio of the company includes a category of medicinal products aimed at elimination of pain and joint inflammation. One of them is Nimedar, a medicinal product, which can relieve pain, inflammation and stiffness in joints quickly. Medicinal product Nimedar is available in two forms - in the form of granules (in a sachet) and in the form of gel (with a transdermal carrier of the active substance). Nimedar in granules is used for systemic treatment of acute pain. Nimedar gel is used for local treatment of pathological states of the musculoskeletal system as part of comprehensive treatment.
The report “Peculiarities of Treatment of Combined Injuries of Massive Rotator Cuff Ruptures of the Shoulder Joint” was presented Igor Zazirnyi, Doctor of Medicine, Professor, Head of the Orthopedics, Traumatology and Sports Medicine Center of the Clinical Hospital “Feofaniya” of the State Management of Affairs, and Viacheslav Yevseienko, Candidate of Medicine, Orthopaedic Trauma Surgeon. The specialists described the peculiarities of the use of various medicinal products for treatment of rotator cuff ruptures of the shoulder joint. In particular, they talked about the relevance and efficiency of use of the medicinal product “Nimedar in granules No. 30” manufactured by “Pharmaceutical Firm “Darnitsa” PrJSC as compared with other medicinal products of foreign manufacture. Conclusions presented during the report were drawn from clinical studies held at the Orthopedics, Traumatology and Sports Medicine Center of the Clinical Hospital “Feofaniya”.
Within the scope of the observation, a significant reduction of the pain syndrome according to the visual analog scale (the method of subjective assessment of pain) from strong to no pain was noted. In the system of multimodal anesthesia, the use of the drug “Nimedar in granules No. 30” also led to a decrease of administration of anesthetics after arthroscopic interventions and a positive dynamics of the pain syndrome. The obtained effect of the drug “Nimedar in granules No. 30” was not inferior to the effect of the use of foreign drugs with the same active substance.
The lesser the severity of morning stiffness and functional knee joint disorders was and the lower the subjective score of the pain syndrome according to the visual analog scale was, the better the functional outcome was considered to be. The need for pain management medications after surgery in patients and the emergence of adverse reactions in patients were also assessed.
Based on the results obtained, it can be concluded that the medicinal product “Nimedar in granules No. 30” has an efficient analgesic and anti-inflammatory effect, has a high safety profile, what makes it possible to use it in the system of treatment and prevention of degenerative-dystrophic diseases of the spine and joints and in the system of multimodal anesthesia (patients taking “Nimedar in granules No. 30” were given less anesthetic drugs, including opioids) after endoscopic surgeries on joints.
Thus, according to the results of the study, the domestic manufacturer – the leader of trust of Ukrainians, “Pharmaceutical Firm “Darnitsa” PrJSC, has proved the high level of quality of manufacturing of medicinal products in accordance with GMP requirements once again.